KRAS and non-small cell lung carcinoma: We have shed light on molecular mechanisms by which KRAS constitutively active mutations elevate mRNA m6A methylation, thus adding as a new layer of regulating ALKBH5 m6A demethylase activity, as well as gene regulation that fortifies DNA repair–related genes, shielding NSCLC cells from cisplatin-induced DNA damage and cell apoptosis.